| Old Articles: <Older 4021-4030 Newer> |
|---|
 |
The Motley Fool
August 13, 2007
Brian Orelli |
Little Drug, Big Sales Huge increases in revenue usually drive stock prices upward, but Abraxis BioScience's stock has fallen 15% from its high last week, despite releasing a stellar earnings report.   |
The Motley Fool
August 13, 2007
Rich Duprey |
U.K. High Court Forgets to Be NICE A court challenge to place limits on treatment for Alzheimer's disease is upheld. Eisai has said it will appeal the High Court's ruling. It's a bit of a high-stakes gamble. The United Kingdom accounts for just a small portion of Eisai's profits from Aricept. |
The Motley Fool
August 10, 2007
Brian Lawler |
GPC Picking Up the Pieces GPC Biotech announced second-quarter financial results last week, in the shadow of a setback; they are awaiting more data on a crucial drug candidate. |
The Motley Fool
August 10, 2007
Rich Smith |
Foolish Forecast: The Other Hansen Medical robotics specialist Hansen Medical prepares earnings for next weeks report. The past two quarters have been disappointing; what are analysts expecting this time? |
The Motley Fool
August 10, 2007
Brian Lawler |
ViroPharma Whacked by Data Shares of ViroPharma fall after safety issues come to light with one of its drugs. A phase 2 study of their hepatitis C antiviral medication has been halted, with only a slim chance of starting up again. |
The Motley Fool
August 10, 2007
Anders Bylund |
Foolish Forecast: Agilent Mix In advance of Agilent's earnings report, analysts are expecting the testing equipment maker to increase revenues. Agilent is poised to make money with new technologies being developed in electronics and bio-analytics. |
Pharmaceutical Executive
July 30, 2007
Richard Altus |
Avandia Sales Away What did you do when you heard the safety news about Avandia? Here's what the rest of the market did, and why it matters to you. |
Pharmaceutical Executive
July 30, 2007
Louis A. Morris |
Safety Net The new Culture of Drug Safety means embracing the benefit of no doubt about a product's pluses and its minuses. Pharma must learn how patients and prescribers weigh risks and how to spread the word about the advantages. |
Pharmaceutical Executive
July 30, 2007
Walter Armstrong |
Tibotec Gets AIDS With a new wave of "resistant to resistance" HIV drugs, a record of consistent innovation, and a dynamic partnership with AIDS activists, Tibotec is in it to win it. And end it. |
Pharmaceutical Executive
July 30, 2007 |
Tomorrow's Drugs A look at the seven top therapies and technologies vying to deliver the next generation of drugs. |
| <Older 4021-4030 Newer> Return to current articles. |
